$RLMD News

Relmada Therapeutics Increases Authorized Common Stock From 150M To 200M Shares Following Shareholder Approval

Relmada Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call

Relmada Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate

Piper Sandler Initiates Coverage On Relmada Therapeutics with Overweight Rating, Announces Price Target of $12

Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

Relmada Therapeutics Inc (NASDAQ:RLMD) Reports Q4 2025 Earnings Miss, Stock Declines

Relmada Therapeutics Q4 EPS $(0.27) Misses $(0.14) Estimate

Relmada Therapeutics shares are trading higher after the company reported 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer. Also, the company announced a $160 million private placement.

Relmada Therapeutics shares are trading higher after the company reported 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer. Also, the company announced a $160 million private placement.

Why Is Relmada Therapeutics Stock Soaring Monday?

Market-Moving News for March 9th

Relmada Therapeutics Announces Private Placement Of $160M

Relmada Therapeutics Announces 12-month Interim Data From Its Ongoing Phase 2 Trial Of NDV-01 For High-risk Non-muscle Invasive Bladder Cancer

LUCID CAPITAL MARKETS Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $14

Relmada Therapeutics Files For Common Stock Offering Of Up To $100M

Leerink Partners Upgrades Relmada Therapeutics to Outperform, Announces $8 Price Target

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications